Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Papers of the Week
Annotation


Town T, Zolton J, Shaffner R, Schnell B, Crescentini R, Wu Y, Zeng J, Delledonne A, Obregon D, Tan J, Mullan M. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro. J Neurosci Res. 2002 Aug 1;69(3):362-72. PubMed Abstract


Corresponding Author: Michael Mullan
Comments on Paper and Primary News
  Comment by:  Inez Vincent, ARF Advisor
Submitted 24 July 2002  |  Permalink Posted 24 July 2002
  I recommend this paper

This study is signficant because it demonstrates that soluble extracellular Aβ can cause cdk5 activation and tau hyperphosphorylation. Also, the effects of Aβ on differentiated neurons are easier to interpret because under these conditions, other cell cycle-associated kinases that might phosphorylate tau are markedly downregulated. I suppose the cells were stably transfected with p35. I am curious to know whether this transfection alone led to increases in tau phosphorylation, or whether the changes described were seen in the presence of Aβ alone. Also, what was the end result? Did tau hyperphosphorylation lead to neuronal death?

View all comments by Inez Vincent

  Comment by:  Michael Mullan
Submitted 1 August 2002  |  Permalink Posted 1 August 2002
  I recommend this paper

Reply to Vincent comment, from J. Tan, T. Town and M. Mullan. To answer the first question, yes, the p35 overexpressing N2a cells were stably transfected with the pUSEamp plasmid containing the p35 cDNA sequence, and maintained in G418 throughout the course of the experiments. Transfection with p35 vector alone did lead to a modest but significant increase in tau phosphorylation versus mock vector transfection as detected by mAbs AT8, AT270 and pAbs pS199 and pS396. When comparing mock-vector transfected N2a cells to the p35-overexpressing variety, p25 levels are much higher in the latter group, suggesting that increased p25 levels associated with p35 overexpression could be responsible for this effect. That having been stated, we only observed a dose-dependent effect (from 1 to 5 microM) of sAβ1-42 in the p35-overexpressing N2a cells, and not in the mock-transfected variety. Thus, it seems that overexpression of p35 sensitizes the system to the effects of sA β. In our hands, with these relatively low doses of A β in soluble form, we did not observe significant neurotoxicity....  Read more

  Comment by:  Inez Vincent, ARF Advisor
Submitted 1 August 2002  |  Permalink Posted 1 August 2002
  I recommend this paper

In response to the comment by Tan, et al.:
The use of primary rat neurons in Tsai's study and a differentiated human neuronal line in the present study may account for the differences in sensitivity to amyloid. However the finding that soluble extracellular A β modulates intracellular neuronal cdk5 activity is important. It may explain the formation of NFT at sites remote from plaques in the P301L transgenic mice for instance (Gotz, 2001; and Lewis 2001), and perhaps in AD as well. I wonder if it would not be worth testing this idea in vivo, for instance, by infusing soluble A β throughout the brain of a wildtype mouse, and determining whether cdk5 activity is similarly affected, and if there is a pattern of differential neuronal vulnerability. That would be exciting!

View all comments by Inez Vincent
  Submit a Comment on this Paper
Cast your vote and/or make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
 
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad